| Paper | Authors | Journal | Year | Type |
|---|
| iGlarlixi for the simplification of more complex insulin regimens in type 2 diabetes patients with good glycaemic control | Taybani ZJ et al. | Frontiers in endocrinology | 2026 | Observational Study |
| Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study | Zhang S et al. | Diabetes, obesity & metabolism | 2026 | Randomized Controlled Trial |
| Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN | Ni J et al. | Diabetes, obesity & metabolism | 2026 | Randomized Controlled Trial |
| Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study | Li X et al. | Diabetes, obesity & metabolism | 2026 | Randomized Controlled Trial |
| Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial | Fountoulakis N et al. | Diabetes, obesity & metabolism | 2026 | Randomized Controlled Trial |
| Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial | Novodvorský P et al. | Diabetes, obesity & metabolism | 2026 | Randomized Controlled Trial |
| Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study | Gu W et al. | Diabetes, obesity & metabolism | 2026 | Randomized Controlled Trial |
| Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study | Malik RA et al. | Diabetes, obesity & metabolism | 2025 | Observational Study |
| Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study | Haluzík M et al. | Diabetes, obesity & metabolism | 2025 | Clinical Trial, Phase IV |
| Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study | Kaneto H et al. | Advances in therapy | 2025 | Observational Study |
| Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes | Shah VN et al. | Diabetes, obesity & metabolism | 2025 | Clinical Trial, Phase IV |
| Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes | Frías JP et al. | Diabetes, obesity & metabolism | 2025 | Clinical Trial, Phase IV |
| Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial | Seufert J et al. | Diabetes, obesity & metabolism | 2025 | Observational Study |
| The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial | Liu M et al. | Diabetes, obesity & metabolism | 2024 | Randomized Controlled Trial |
| Effect of lixisenatide on liquid gastric emptying in type 2 diabetes - Implications for the use of GLP-1 receptor agonists before procedures | Kovoor JG et al. | Journal of diabetes and its complications | 2024 | Randomized Controlled Trial |
| Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study | Malik RA et al. | Diabetes, obesity & metabolism | 2024 | Observational Study |
| Trial of Lixisenatide in Early Parkinson's Disease | Meissner WG et al. | The New England journal of medicine | 2024 | Randomized Controlled Trial |
| Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring | Kawaguchi Y et al. | Journal of diabetes investigation | 2024 | Randomized Controlled Trial |
| Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial | McInnes N et al. | Diabetes, obesity & metabolism | 2023 | Randomized Controlled Trial |
| iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis | Guo X et al. | Diabetes, obesity & metabolism | 2023 | Randomized Controlled Trial |
| The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study | Terauchi Y et al. | Advances in therapy | 2022 | Observational Study |
| Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial | Yang W et al. | Diabetes, obesity & metabolism | 2022 | Randomized Controlled Trial |
| A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes | Barrientos-Pérez M et al. | Pediatric diabetes | 2022 | Randomized Controlled Trial |
| Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes | Ferrannini E et al. | Diabetes, obesity & metabolism | 2022 | Randomized Controlled Trial |
| Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes | Kawaguchi Y et al. | Journal of diabetes investigation | 2022 | Randomized Controlled Trial |
| Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial | Iizuka K et al. | Diabetes, obesity & metabolism | 2021 | Clinical Trial |
| Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study | Kuwata H et al. | Journal of diabetes investigation | 2021 | Observational Study |
| iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial | Yabe D et al. | Journal of diabetes investigation | 2021 | Clinical Trial |
| Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies | Liu F et al. | Journal of diabetes investigation | 2021 | Randomized Controlled Trial |
| The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control | Gautier T et al. | Journal of diabetes science and technology | 2021 | Randomized Controlled Trial |